Gecacitinib
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-01 — Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.: Matching-adjusted indirect comparison (observational) ranked gecacitinib above fedratinib, pacritinib, and momelotinib on spleen-volume and symptom responses in ruxolitinib-pretreated MF, with lower GI adverse-event and discontinuation rates — first comparative-effectiveness positioning of gecacitinib among approved second-line JAK inhibitors. (novelty: 3)
Open questions
Related
Contributing findings
Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.
01-sep-2026
novelty 3
per-area 3
introduces